These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21120332)

  • 21. Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease.
    Crivaro AN; Mucci JM; Bondar CM; Ormazabal ME; Ceci R; Simonaro C; Rozenfeld PA
    PLoS One; 2019; 14(5):e0217780. PubMed ID: 31150494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.
    Wall St J (East Ed); 2005 Nov; ():A1, A15. PubMed ID: 16502532
    [No Abstract]   [Full Text] [Related]  

  • 23. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.
    Jayasundara K; Hollis A; Krahn M; Mamdani M; Hoch JS; Grootendorst P
    Orphanet J Rare Dis; 2019 Jan; 14(1):12. PubMed ID: 30630499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
    Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limits on use of health economic assessments for rare diseases.
    Hyry HI; Stern AD; Cox TM; Roos JC
    QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.
    Ollendorf DA; Chapman RH; Pearson SD
    Value Health; 2018 May; 21(5):547-552. PubMed ID: 29753351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.
    Schuller Y; Hollak CE; Biegstraaten M
    Orphanet J Rare Dis; 2015 Jul; 10():92. PubMed ID: 26223689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
    Mentzakis E; Stefanowska P; Hurley J
    Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods.
    Bourke SM; Plumpton CO; Hughes DA
    Value Health; 2018 May; 21(5):538-546. PubMed ID: 29753350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orphan drug policies and use in pediatric nephrology.
    Karpman D; Höglund P
    Pediatr Nephrol; 2017 Jan; 32(1):1-6. PubMed ID: 27738765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Competing for public funding of medicines to treat rare disorders in New Zealand.
    Crausaz S
    Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
    [No Abstract]   [Full Text] [Related]  

  • 35. Sustainable rare diseases business and drug access: no time for misconceptions.
    Rollet P; Lemoine A; Dunoyer M
    Orphanet J Rare Dis; 2013 Jul; 8():109. PubMed ID: 23879976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How can the risk that orphan drugs present to budgets be managed better?
    O'Neill C
    Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Medicoeconomic data on rare disease drugs: a move towards more transparency?].
    Schwebig A; Duguet C; Ferry A; Bougé C; Fagon JY; Bismuth C; Ramon J
    Presse Med; 2012 May; 41 Suppl 1():S57-64. PubMed ID: 22487716
    [No Abstract]   [Full Text] [Related]  

  • 39. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Consequences of the judicialization of health policies: the cost of medicines for mucopolysaccharidosis].
    Diniz D; Medeiros M; Schwartz IV
    Cad Saude Publica; 2012 Mar; 28(3):479-89. PubMed ID: 22415180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.